Published in

BioMed Central, Stem Cell Research and Therapy, 1(5), 2014

DOI: 10.1186/scrt390

Links

Tools

Export citation

Search in Google Scholar

Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes

Journal article published in 2014 by Jean-Sébastien Hulot ORCID, Francesca Stillitano, Joe Elie Salem, Jason C. Kovacic ORCID, Valentin Fuster, Roger J. Hajjar
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Pluripotent stem cells (PSCs) represent an appealing source from which to develop cell replacement therapies. Different initiatives have been launched to promote their development toward clinical applications. This article will review the main questions that should be considered before translating PSC-derived cardiomyocytes into clinical investigations, including the development of good manufacturing practice-level PSC lines, the development of efficient protocols to generate pure populations of cardiac myocytes, and the development of techniques to improve the retention and survival rate of transplanted cells.